查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
粒子治疗系统的全球市场-2022-2029
市场调查报告书
商品编码
1140686

粒子治疗系统的全球市场-2022-2029

Global Particle Therapy System Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 170 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场动态

全球癌症患者数量的增加正在推动粒子治疗系统市场的发展。

根据美国国家癌症研究所的数据，预计 2020 年美国将诊断出 180 万例新的癌症病例，并将登记 606,520 例死于该疾病的病例。到 2020 年，大约 43.0% 的男性确诊癌症将是前列腺癌、结直肠癌或肺癌。对于女性来说，肺癌、乳腺癌和结直肠癌是最常见的三种癌症，约占女性新诊断癌症的 50%。随着癌症患者数量的增加，对治疗系统的需求将增加，在预测期内为粒子治疗系统市场提供增长机会。

此外，消费者对粒子治疗系统的认识不断提高，也推动了市场的增长。此外，与传统放射疗法相比，质子疗法的优势使患者转向质子疗法。多项研究表明，与标准放射治疗相比，质子治疗可能会引起短期和长期副作用，包括减少继发性肿瘤发展的机会和提高生活质量。因此，全球范围内从传统疗法向质子疗法的转变正在增加。

地理渗透。

北美是预测期内的主要地区。

该研究按地区分析了全球市场的粒子治疗系统市场，包括北美、南美、欧洲、亚太地区、中东和非洲。

就价值和数量而言，北美占全球粒子治疗系统市场的最大份额，其次是欧洲和亚太地区。2022年北美多重检测市场将由美国主导。该市场主要由美国技术先进的医疗保健基础设施和政府机构不断增加的资金推动。

此外，预计亚太地区的粒子治疗系统市场在预测期内将以最快的复合年增长率增长。在亚太地区，由于患者人数的增加、医疗基础设施的快速发展以及製药公司研发活动的显着增加，预计中国将主导市场。

竞争格局。

由于粒子治疗系统品牌众多，粒子治疗系统市场竞争激烈。主要的粒子治疗系统公司包括 Danfysik A/S、Advanced Oncotherapy PLC、Hitachi, Ltd.、Optivus Proton Therapy, Inc、Mevion Medical Systems, Inc、Provision Healthcare, LLC、Protom International, Inc、Ion Beam Applications Sa (IBA)、 Sumitomo Heavy Industries, Ltd.、Varian Medical Systems, Inc.、HD Biosciences Co, Ltd.、Hitachi, Ltd. 和Toshiba。决定性的参与者正在为粒子治疗系统市场的全球增长采用新产品和服务的推出和扩张战略。2021年6月，Advanced Oncotherapy签订合同，以1.07亿美元提供三间LIGHT系统治疗室。本合同金额适用于轻型设备的采购、安装及长期维修保修合同。该系统将安装在瑞士的质子治疗设施中。2022年8月，用于治疗癌症患者的质子粒子束治疗的主要製造商和供应商Mevion Medical Systems向中国同济医科大学同济医院交付了质子束治疗系统“MEVION S250i”。质子治疗优于放射治疗，因为它减少了对周围健康组织和敏感器官的不必要辐射暴露。质子束疗法已被用于减少有害辐射，并且粒子疗法的采用正在增加。

COVID-19 的影响。它对全球粒子治疗系统市场产生了负面影响。

据估计，COVID-19 大流行将抑制预测期内粒子治疗系统市场的增长。在开发 COVID-19 疫苗的同时，由于采用率下降，市场在 2020 年出现了小幅下滑。政府提供择期手术指南，以减轻卫生系统的压力、减少疾病传播并节省个人防护设备。因此，粒子治疗系统市场在 2020 年出现温和下滑。在大流行期间，全球癌症负担增加了 20%。这可能是由于诊断和治疗程序的推迟。几乎所有癌症治疗中心都提供粒子治疗紧急服务，在大流行期间到中心治疗的患者人数有所下降。由于封锁导致的製造设施关闭扰乱了供应链，临床试验的招聘减少对 Covid 大流行中整个粒子治疗系统市场的增长产生了负面影响。

全球粒子治疗系统市场报告提供了大约 77 个市场数据表、71 个数字和 170 页的结构。

目录

第一章 调查方法和范围

  • 调查方法
  • 调查目的和范围

第二章市场定义和概述

第三章执行摘要

  • 按产品/服务划分的市场细分
  • 按类型划分的市场细分
  • 按系统划分的市场细分
  • 按癌症类型划分的市场细分
  • 按应用划分的市场细分
  • 区域市场细分

第四章市场动态

  • 市场影响因素
    • 促进者
      • 癌症患病率增加
      • 在临床试验中越来越多地采用粒子疗法
    • 抑製剂
      • 治疗的可负担性和可及性
    • 商机
    • 影响分析

第五章行业分析

  • 波特五力分析
  • 供应链分析
  • 价值链分析
  • PEST分析
  • 定价分析
  • 监管分析
  • 保险报销分析
  • 未满足的需求
  • 专利趋势

第 6 章 COVID-19 分析

  • COVID-19 的市场分析
    • COVID-19 之前的市场情景
    • COVID-19 的当前市场情景
    • COVID-19 后或未来情景
  • COVID-19 中的价格动态
  • 供需谱
  • 大流行期间与市场相关的政府努力
  • 製造商的战略举措
  • 概括

第 7 章按产品/服务分类

  • 机器
  • 服务

第 8 章 按类型

  • 质子治疗
  • 重离子放疗

第 9 章 按系统

  • 多房间系统
  • 单人房

第10章按癌症类型

  • 前列腺癌
  • 肺癌
  • 乳腺癌
  • 儿童癌症
  • 其他（头颈癌）

第 11 章 按申请

  • 治疗用途
  • 调查使用

第12章按地区

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 欧洲其他地区
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美地区
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 亚太其他地区
  • 中东/非洲

第十三章 竞争格局

  • 竞争情景
  • 市场定位/市场份额分析
  • 併购分析

第十四章公司简介

  • Danfysik A/S
    • 公司简介
    • 产品/服务组合和描述
    • 主要亮点
    • 财务概览
  • 先进的肿瘤治疗 PLC
  • Hitachi, Ltd.
  • Optivus Proton Therapy, Inc.
  • Mevion Medical Systems, Inc.
  • Provision Healthcare, LLC
  • Protom International, Inc.
  • Ion Beam Applications Sa（IBA）
  • Sumitomo Heavy Industries, Ltd.
  • Varian Medical Systems, Inc.（List Not Exhaustive）

第 15 章 重要注意事项

第 16 章 数据管理

简介目录
Product Code: DMHCIT3083

Market Overview

Particle Therapy System Market was valued at USD YY million in 2021. It is forecasted to reach USD YY million by 2029, growing at a CAGR of 8.6% during the forecast period (2022-2029).

Particle therapy is a form of external beam radiotherapy using beams of energetic neutrons, protons, or other heavier positive ions for cancer treatment. Proton Therapy System provides cancer therapy via pencil beam spot scanning technology. Particle therapy could minimize the extent and severity of normal tissue injury. Particle therapy is one of the cutting-edge areas of external beam radiotherapy. Growth in the particle therapy market is primarily driven by factors such as the several advantages offered by particle therapy over photon therapy, the growing prevalence of cancer, the increasing adoption of particle therapy in clinical trials, and the rising number of particle therapy centers worldwide.

Market Dynamics: Rising number of cancer cases globally drives particle therapy systems market.

According to the National Cancer Institute, in 2020, an estimated 1.8 million new cancer cases will be diagnosed in the US, and 606,520 mortalities will be registered from the disease. In 2020, prostate, colorectal, and lung cancers accounted for around 43.0% of all cancers diagnosed in men. For women, the three most common cancers are lung, breast, and colorectal, accounting for around 50% of all new cancer diagnoses in women. With the rising cancer cases, the demand for therapy systems will increase, offering growth opportunities to the particle therapy system market during the forecast period.

Moreover, increasing consumers' awareness of particle therapy systems drives the market growth. Also, the advantages of proton therapy over conventional radiotherapy divert patients towards proton therapy. Several types of research have stated that proton therapy can cause short- and long-term side effects compared to standard radiation therapy, which includes reducing the chances of secondary tumors occurrence and improving quality of life. Therefore, the transition from conventional therapy to proton therapy is increasing globally.

Market Segmentation: The treatment segment accounted for the highest share in global particle therapy system market.

Based on the application, the particle therapy system market has been classified into treatment and research applications.

The treatment application segment dominated the total market in 2019. This dominance is backed by its growing use in discovery, manufacturing, and drug development. Moreover, the rising adoption of particle therapy systems in various cancer diagnoses, including immune system diseases, bone marrow diseases, and other infectious diseases, are driving the market.

Based on the type, the particle therapy system market has been classified into proton therapy systems and heavy ion therapy.

The proton therapy segment dominated the global particle therapy system market in the forecast period, backed by several advantageous factors, such as the high degree of precision, reduced side effects associated with proton therapy, and shorter treatment time. These factors are accelerating the growth of the proton therapy market, a transition from heavy ion therapy.

Geographical Penetration: North America is the dominating region during the forecast period.

Based on geography, the study analyzes the particle therapy system market in the global market, including North America, South America, Europe, Asia-Pacific, and the Middle East & Africa.

North America dominates the global particle therapy system market with the largest share in terms of value and volume globally, followed by Europe and the Asia Pacific. The US dominated the North American multiplex assay market in 2022. The market is mainly driven by the presence of well-developed technologically advanced healthcare infrastructure in the US coupled with increased funding by government agencies.

Moreover, Asia Pacific is projected to grow at the fastest CAGR in the particle therapy system market during the forecast period. China is estimated to dominate the Asia Pacific market due to the increase in patient population, rapidly developing healthcare infrastructure and significant rise in R&D activities in pharmaceutical companies in the region.

Competitive Landscape:

The particle therapy system market is highly competitive, owing to the large presence of particle therapy system brands. The key particle therapy system players include Danfysik A/S, Advanced Oncotherapy PLC, Hitachi, Ltd., Optivus Proton Therapy, Inc., Mevion Medical Systems, Inc., Provision Healthcare, LLC, Protom International, Inc., Ion Beam Applications Sa (IBA), Sumitomo Heavy Industries, Ltd., Varian Medical Systems, Inc., HD Biosciences Co., Ltd. The crucial players are adopting new Product & Service launches and expansion strategies for global growth in the particle therapy system market. In June 2021, Advanced Oncotherapy signed a deal to provide three LIGHT system treatment rooms for US$107mln. This contract value is used for the purchase of light equipment, installation and long-term maintenance and warranty agreement. This system is installed in a proton therapy center in Switzerland. August 2022, Mevion Medical Systems, a leading manufacturer and supplier of proton particle therapy for the treatment of cancer patients delivered the MEVION S250i Proton therapy system to Tongji Hospital of Tongji Medical College, China. Proton therapy is superior to radiation therapy; that can reduce the unnecessary radiation exposure to surrounding healthy tissue and sensitive organs at risk. The adoption of particle therapy is increasing due to the adoption of proton particle therapy to reduce harmful radiation.

COVID-19 Impact: Negative impact on the global particle therapy system market.

The COVID-19 pandemic is estimated to derail the particle therapy system market growth during the forecast period. The market has seen a modest decrease in 2020, backed by the decline in its adoption while developing vaccines for COVID-19. Governments have provided guidelines for elective surgeries to reduce the strain on the healthcare system, decrease disease transmission, and conserve personal protective equipment. Therefore, a modest downfall was witnessed by the particle therapy system market in 2020. The global cancer burden increased by 20% during the pandemic. It can be attributed to the postponement of diagnosis and treatment procedures. Particle therapy emergency services were available in almost all cancer treatment centers, and the number of patients visiting centers for treatment has reduced during the pandemic. Closed manufacturing facilities due to lockdowns have disrupted supply chains, and reduced recruitments for clinical trials negatively impacted the growth of the overall particle therapy devices market in the Covid Pandemic.

The global particle therapy system market report would provide an access to approximately 77 market data tables, 71 figures and 170 pages

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

  • 3.1. Market Snippet by Product & Services
  • 3.2. Market Snippet by Type
  • 3.3. Market Snippet by System
  • 3.4. Market Snippet by Cancer Type
  • 3.5. Market Snippet by Application
  • 3.6. Market Snippet by Region

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Growing Prevalence of Cancer
      • 4.1.1.2. Growing Adoption of Particle Therapy in Clinical Trials
    • 4.1.2. Restraints:
      • 4.1.2.1. Affordability and Accessibility of Treatments
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Value Chain Analysis
  • 5.4. PEST Analysis
  • 5.5. Pricing Analysis
  • 5.6. Regulatory Analysis
  • 5.7. Reimbursement Analysis
  • 5.8. Unmet Needs
  • 5.9. Patent Trends

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Product & Services

  • 7.1. Introduction
  • 7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product & Services Segment
  • 7.3. Market Attractiveness Index, By Product & Services Segment
    • 7.3.1. Equipment*
      • 7.3.1.1. Introduction
      • 7.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 7.3.2. Services

8. By Type

  • 8.1. Introduction
  • 8.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type Segment
  • 8.3. Market Attractiveness Index, By Type Segment
    • 8.3.1. Proton Therapy*
      • 8.3.1.1. Introduction
      • 8.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 8.3.2. Heavy Ion Therapy

9. By System

  • 9.1. Introduction
  • 9.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By System Segment
  • 9.3. Market Attractiveness Index, By System Segment
    • 9.3.1. Multi-Room System*
      • 9.3.1.1. Introduction
      • 9.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 9.3.2. Single-Room System

10. By Cancer Type

  • 10.1. Introduction
  • 10.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cancer Type Segment
  • 10.3. Market Attractiveness Index, By Cancer Type Segment
    • 10.3.1. Prostate Cancer*
      • 10.3.1.1. Introduction
      • 10.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 10.3.2. Lung Cancer
    • 10.3.3. Breast Cancer
    • 10.3.4. Pediatric Cancer
    • 10.3.5. Others (Head and Neck Cancer)

11. By Application

  • 11.1. Introduction
  • 11.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
  • 11.3. Market Attractiveness Index, By Application
    • 11.3.1. Treatment Application*
      • 11.3.1.1. Introduction
      • 11.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 11.3.2. Research Application

12. By Region

  • 12.1. Introduction
  • 12.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
  • 12.3. Market Attractiveness Index, By Region
  • 12.4. North America
    • 12.4.1. Introduction
    • 12.4.2. Key Region-Specific Dynamics
    • 12.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product & Services
    • 12.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 12.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By System
    • 12.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cancer Type
    • 12.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 12.4.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 12.4.8.1. U.S.
      • 12.4.8.2. Canada
      • 12.4.8.3. Mexico
  • 12.5. Europe
    • 12.5.1. Introduction
    • 12.5.2. Key Region-Specific Dynamics
    • 12.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product & Services
    • 12.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 12.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By System
    • 12.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cancer Type
    • 12.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 12.5.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 12.5.8.1. Germany
      • 12.5.8.2. U.K.
      • 12.5.8.3. France
      • 12.5.8.4. Italy
      • 12.5.8.5. Spain
      • 12.5.8.6. Rest of Europe
  • 12.6. South America
    • 12.6.1. Introduction
    • 12.6.2. Key Region-Specific Dynamics
    • 12.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product & Services
    • 12.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 12.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By System
    • 12.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cancer Type
    • 12.6.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 12.6.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 12.6.8.1. Brazil
      • 12.6.8.2. Argentina
      • 12.6.8.3. Rest of South America
  • 12.7. Asia Pacific
    • 12.7.1. Introduction
    • 12.7.2. Key Region-Specific Dynamics
    • 12.7.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product & Services
    • 12.7.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 12.7.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By System
    • 12.7.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cancer Type
    • 12.7.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 12.7.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 12.7.8.1. China
      • 12.7.8.2. India
      • 12.7.8.3. Japan
      • 12.7.8.4. Australia
      • 12.7.8.5. Rest of Asia Pacific
  • 12.8. Middle East and Africa
    • 12.8.1. Introduction
    • 12.8.2. Key Region-Specific Dynamics
    • 12.8.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product & Services
    • 12.8.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 12.8.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By System
    • 12.8.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cancer Type
    • 12.8.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 12.8.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

13. Competitive Landscape

  • 13.1. Competitive Scenario
  • 13.2. Market Positioning/Share Analysis
  • 13.3. Mergers and Acquisitions Analysis

14. Company Profiles

  • 14.1. Danfysik A/S*
    • 14.1.1. Company Overview
    • 14.1.2. Product & Services Portfolio and Description
    • 14.1.3. Key Highlights
    • 14.1.4. Financial Overview
  • 14.2. Advanced Oncotherapy PLC
  • 14.3. Hitachi, Ltd.
  • 14.4. Optivus Proton Therapy, Inc.
  • 14.5. Mevion Medical Systems, Inc.
  • 14.6. Provision Healthcare, LLC
  • 14.7. Protom International, Inc.
  • 14.8. Ion Beam Applications Sa (IBA)
  • 14.9. Sumitomo Heavy Industries, Ltd.
  • 14.10. Varian Medical Systems, Inc. (List Not Exhaustive)

15. Premium Insights

16. DataM Intelligence

  • 16.1. Appendix
  • 16.2. About Us and Services
  • 16.3. Contact Us